Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

New medication safety information service sends recall alert across the USA

IGuard : 29 November, 2007  (New Product)
In a patient safety world first,, a new, free medication safety information service, has sent the first personalised electronic nationwide recall alert in the USA to patients who take gabapentin medication.
The recall, voluntarily initiated by Ranbaxy Laboratories, affects more than 73 million tablets worldwide. More than 400 iGuard registrants take gabapentin and received the alerts.

'We are really proud to be part of this first patient-centric medication recall,' said Dr Hugo Stephenson, founder and president of iGuard. 'Based on the overwhelmingly positive reaction we've had from patients and doctors, it's about time we started thinking about who needs this information the most – patients.'

Mrs J Rogers, a recent registrant with iGuard, said, 'I never would have heard about the (gabapentin) recall had it not come to me directly. I'm surprised and shocked that such a system wasn't in existence already.'

Stephenson said, 'For years we have taken for granted that we'll get personal recall notices for the cars we buy. Now the same opportunity is finally available for people that take medications.'

iGuard provides patients with a simple way to check interactions between their medications and receive personalised alerts and recall notices as they occur. In its first month of operation, and still in its ‘beta’ stage, iGuard has registered almost 7,000 users and is averaging between 250 and 500 new registrations per day.

Despite recent attempts to communicate drug safety questions earlier, agencies such as the FDA and manufacturers have been hampered in their ability to reach patients with safety communications. iGuard represents a simple way for patients to voluntarily register for alerts without compromising their privacy. iGuard receives information for its alerts from regulators such as the FDA, from manufacturers, and from major journals that it monitors for breaking research.

National drug safety experts, including representatives from the Center for Medicine in the Public Interest (CMPI) and the Critical Path Institute (CPI) are calling for an improved approach to providing consumers with real time and individualised information about the risks and benefits of drugs on the market.

With nearly half of all Americans taking a prescription drug and one in six taking three or more, the opportunity for improved health and safer, more effective prescribing is significant.

In addressing this growing problem, drug safety experts are urging people to take a more active role in understanding the risks and benefits of their medicines through real time updates.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   Â© 2012
Netgains Logo